Osteogenic differentiation of bone marrow stromal cells is hindered by the presence of intervertebral disc cells. by Chan, Samantha C W et al.
RESEARCH ARTICLE Open Access
Osteogenic differentiation of bone marrow
stromal cells is hindered by the presence of
intervertebral disc cells
Samantha C. W. Chan1,2, Adel Tekari1, Lorin M. Benneker3,4, Paul F. Heini5 and Benjamin Gantenbein1,4*
Abstract
Background: Clinical observations indicate that the presence of nucleus pulposus (NP) tissue during spinal fusion
hinders the rate of disc ossification. While the underlying mechanism remains unknown, this observation could be
due to incomplete removal of NP cells (NPCs) that secrete factors preventing disc calcification, such as bone
morphogenetic protein (BMP) antagonists including noggin and members of the DAN (differential screening
selected gene aberrative in neuroblastoma) family.
Methods: Monolayer human bone marrow-derived mesenchymal stem cells (MSCs) were cocultured withNPCs and
annulus fibrosus cells (AFCs) embedded in alginate for 21 days. At the end of coculture, MSCs were stained for
mineral deposition by alizarin red, and relative expression of bone-related genes [Runt-related transcription factor 2,
(RUNX2), Osteopontin (OPN), and Alkaline phosphatase (ALP)] and ALP activity were analyzed. Relative expression of
three BMP antagonists, chordin (CHRD), gremlin (GREM1), and noggin (NOG), was determined in primary human NPCs
and AFCs. These cells were also stained for Gremlin and Noggin by immunocytochemistry.
Results: Alizarin red staining showed that MSC osteogenesis in monolayer cultures was inhibited by coculture with
NPCs or AFCs. ALP activity and RT-PCR analyses confirmed these results and demonstrated inhibition of
osteogenesis of MSC in the presence of disc cells. NOG was significantly up-regulated in MSCs after coculture.
Relative gene expression of intervertebral disc (IVD) cells showed higher expression of GREM1 in NPCs than in AFCs.
Conclusions: We show that primary IVD cells inhibit osteogenesis of MSCs. BMP inhibitors NOG, GREM1 and CHRD
were expressed in IVD cells. GREM1 appears to be differentially expressed in NPCs and AFCs. Our results have
implications for the design and development of treatments for non-union in spinal fusion.
Keywords: Spinal non-fusion, Osteogenesis, Bone marrow, Mesenchymal stem cells, Human nucleus pulposus cells,
Human annulus fibrosus cells, Relative gene expression
Background
Spinal fusion is a surgical procedure to join two or more
vertebral bodies together by removal of the interverte-
bral disc (IVD). During this process, the disc is dissected
and a spinal cage is placed in the disc space together
with either an allogeneic or autogenic bone graft or a
synthetic bone substitute with the support of growth
factors. To obtain segmental stability, the procedure
relies on the natural bone growth processes of the spine.
Although excision of an IVD is a standard procedure for
spinal fusion, the development of minimally invasive
operations, such as laparoscopic anterior spinal fusion
with cages, may result in incomplete discectomy.
Based on a retrospective study, Lee et al. [1] and
Watkins et al. [2] reported non-fusion rates ranging
from 0–30 %. Based on clinical observations, the pres-
ence of nucleus pulposus (NP) tissue appears to hinder
the rate of disc ossification after spinal fusion surgery
[3]. Further evidence supporting inhibition of ossifica-
tion was gained in an animal study performed on pigs,
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which also suggested a delay in bone formation during
spinal fusion in the presence of NP tissue [4]. By under-
standing the underlying mechanism of this process,
strategies to enhance spinal fusion can be investigated.
The NP is derived from the notochord of mesodermal
origin [5]. During development, the notochord in the
human embryo gradually breaks down and is enclosed
within the primitive annulus fibrosus (AF) that later
forms the primitive NP [6]. Noggin (NOG) and sonic
hedgehog are expressed during notochord development
[7]. IVD cells secrete bone morphogenetic protein
(BMP)-binding proteins, such as NOG, gremlin (GREM1),
and chordin (CHRD), to block BMP signaling that origi-
nates from the vertebral bodies to provide a BMP-reduced
zone and prevent ossification of the disc [8, 9]. The ex-
pression of these BMP antagonists in IVD cells is import-
ant for normal formation of the disc and plays a role in its
segmental pattern formation [7, 10]. BMPs, which are
members of the transforming growth factor-β superfamily,
play a pivotal role in skeletal development because they
induce commitment of mesenchymal stem cells (MSCs)
toward osteoblasts [11–15]. BMP signals are regulated by
extracellular and intracellular signals through BMP antag-
onists that block BMP signal transduction at multiple
levels [16]. By examining notochord-specific markers,
such as brachyury, a previous study has shown that noto-
chordal cells are present in human discs throughout life
[5]. It is therefore possible that nucleus pulposus cells
(NPCs) also express certain BMP antagonists. CHRD has
also been reported to be expressed in both bovine
and human IVD tissues [17]. Otherwise, there is
limited information on the expression of the BMP an-
tagonists in human IVDs.
The balance between bone, cartilage, and IVDs in
skeletal development and its homeostasis are critical to
understanding the development of disease [16, 18, 19]. It
is thus important to investigate the reported BMP antag-
onists that are likely secreted by IVD cells and might in-
fluence the osteogenic differentiation of MSCs and
functions of osteoblasts to improve spinal fusion efficacy.
This issue is significant considering a study on the appli-
cation of high doses of BMP2, which queried the safe
and efficient application of such cytokines in the clinic
[20]. It has been recently shown that specific members
of the differential screening selected gene aberrative in
neuroblastoma (DAN) family [18] and BMP antagonists
such as Noggin might be responsible for delaying and
inhibiting spinal fusion, although such cytokines are ap-
plied at very high doses [16, 21]. Therefore, we hypothe-
sized that NP cells secret cytokines [22, 23] that affect
the metabolism of osteoblasts or bone marrow-derived
MSCs [24]. Here, we investigated the effect of IVD cells
on osteogenesis of MSCs and provide fundamental infor-
mation on which bone-forming inhibitors are secreted
by IVD cells to reveal the mechanism of delayed ossifica-
tion in the presence of NP tissue during spinal fusion.
The first aim was to investigate the role of NPCs and an-
nulus fibrosus cells (AFCs) on the osteogenesis of MSCs.
The second aim was to analyze the natural expression of
candidate BMP inhibitors. To this end, three BMP an-
tagonists, CHRD, GREM1 and NOG, were evaluated at
mRNA and protein levels in enzyme-isolated, low
passage-expanded human IVD cells using gene expres-
sion and immunocytochemical analyses.
Methods
Human donor materials
Human bone marrow and IVD tissues were collected
from patients who underwent spinal surgery. Written
informed consent was obtained from the patients.
The procedure was approved by Ethics Office of the
Canton of Bern. The donors of MSC and IVD sam-
ples used for the coculture experiment are listed in
Table 1. MSCs were isolated from five patients, and
IVD cells were isolated from six patients. Three discs
were symptomatic degenerative discs (SD), two discs
were discs affected by trauma (T), and one patient
was found to have an asymptomatic degenerative disc
(D,T). IVD materials from another eight human do-
nors were used to isolate disc cells for immunocyto-
chemistry and measure the mRNA levels of BMP
antagonists, which are listed in Table 2. Four discs
were symptomatic degenerative discs, two discs were
trauma discs and discs from two patients were
asymptomatic degenerative discs.
Human cell isolation and expansion
Mononuclear cells from bone marrow samples were
isolated by density gradient centrifugation (Histopa-
que-1077, Sigma-Aldrich, Buchs, Switzerland) and
then plated in minimum essential medium alpha (α-
MEM) containing 10 % fetal bovine serum (FBS,
Sigma-Aldrich), 100 U/ml penicillin, 100 mg/ml
streptomycin, and 2.5 ng/ml fibroblast growth factor
2 (PeproTech, London, UK). The MSCs were ex-
panded as monolayers up to passage three to
homogenize the cell populations and increase the cell
number. IVD tissues were processed within 24 h after
isolation and divided into the NP and AF by an expe-
rienced surgeon. Cells from both tissues were sepa-
rated from their native surrounding extracellular
matrix by digestion with 0.19 % pronase (Roche, Ba-
sel, Switzerland) for 1 h and then collagenase type 2
(Worthington, London, UK) overnight (approximately
14 h) as described previously [25]. The disc cells were
expanded in low glucose (1 g/L) Dulbecco’s modified
Eagle’s medium (LG-DMEM) containing 10 % FBS,
100 U/ml penicillin, and 100 mg/ml streptomycin.
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Both cells types were expanded up to passage 2 prior
to coculture experiments (Table 1).
Cell encapsulation and coculture
MSCs were seeded at 2 × 104 cells/well in 12-well
plates. NPCs and AFCs were encapsulated separately
in 1.2 % alginate at a density of 4 Mio/mL using a
syringe (22 G needle) by forming approximately 30 μl
droplets in a 102 mM CaCl2 salt solution [26]. The
NPC and AFC alginate beads (six beads/well) were
maintained in coculture with a monolayer of MSCs in
osteogenic medium (α-MEM) containing 10 % FBS,
100 U/ml penicillin, 100 mg/ml streptomycin, 10 nM
dexamethasone, 5 mM β-glycerophosphate, and 50 μg/ml
ascorbic acid-2-phosphate (all purchased from Sigma-
Aldrich). MSC coculture with empty alginate beads served
as a positive material control (Fig. 1). The negative
control was a MSC monolayer cultured in growth
medium without osteogenic supplements. All cocul-
tures were conducted using culture inserts (0.4-μm
pore size, high pore density, polyethylene tereph-
thalate track-etched, Becton, Dickinson and Company,
Allschwil, Switzerland) to ensure diffusion of cytokines
and no direct cell contact. The cultures were maintained
for 21 days with medium changes three times per week.
Real-time RT-PCR
Relative gene expression of major osteogenic genes, in-
cluding Alkaline Phosphatase (ALP), Runt-related tran-
scription factor 2 (RUNX2), and Osteopontin (OPN),
BMP antagonists NOG and GREM1, and ribosomal 18S
as a reference gene [27] were monitored in MSCs. To
determine the baseline expression levels of BMP an-
tagonists in disc cells, CHRD, NOG and GREM1 gene
expression was monitored in passage-1 primary IVD
cells. Cells were isolated from the extracellular matrix
by enzymatic digestion and then cultured as a monolayer.
This approach was chosen over bead culture to minimize
artifacts from extended in vitro culture. Human-specific
oligonucleotide primers (Table 3) (Microsynth, Balgach,
Switzerland) were designed with Beacon Designer™
software (Premier Biosoft, Palo Alto, CA, USA) based
on nucleotide sequences from GenBank. Amplicons
were generated using a two-step protocol using 61 °C
for 30 s and melting at 95 °C for 15 s with 45 cycles.
Relative gene expression was quantified by application
Table 1 Donors of mesenchymal stem cells (MSCs) and intervertebral disc (IVD) materials for coculture experiments
Bone marrow-derived MSCs IVD cells
Coculture
experiment
MSC donor Birth year Patient age,
years
Sex IVD donor Disc level Grade of disc
degeneration
Birth year Patient age,
years
Sex Type
1 1 1932 81 F 1 L1–L2 Unknown 1988 25 M T
2 2 1951 62 F 1 L1–L2 Unknown 1988 25 M T
3 3 1958 55 M 2 L1–L2 Pfirrmann 2 (CT) 1975 38 M D, T
4 3 1958 55 M 3 L4–L5 Pfirrmann 3 (CT) 1957 56 M SD
5 4 1957 57 F 2 L1–L2 Pfirrmann 2 (CT) 1975 38 M D, T
6 4 1957 57 F 4 L4–L5 Pfirrmann 3 (CT) 1957 56 M SD
7 4 1957 57 F 5 L1–L2 Pfirrmann 1–2 (MRI) 1978 35 M T
8 5 1989 25 M 6 T12–L1 Unknown 1978 36 M SD
MSCs were isolated from five patients and IVD cells were isolated from six patients. F female, M male, L lumbar vertebra, CT computed tomography, MRI magnetic
resonance imaging, T traumatic disc, D degenerative disc, SD symptomatic degenerative disc
Table 2 Donors of IVD materials for cell isolation, and RT-PCR and immunostaining analyses of bone morphogenic protein antagonists
IVD donor Donor code Birth year Sex Patient age, years Disc level Type
1 P38 1978 M 37 L5–S1 SD, modic type II
2 P40 1959 M 56 L4–L5 SD, modic type II
3 P41 1982 M 33 Unknown T
4 P45 1968 M 47 T12–L1 SD
5 P46 1968 M 47 L1–L2 T, D
6 P47 1982 M 33 T12–L1 T,D
7 P48 1941 M 74 L2–L3 T
8 P50 1958 M 57 L5–S1 SD
M male, L lumbar vertebra, T traumatic disc, D degenerative disc, SD symptomatic degenerative disc
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of a threshold cycle (Ct) and calculation of ΔΔCt. The
statistical analysis of 2-ΔΔCt was conducted according
to Livak and Schmittgen [28].
Alkaline phosphatase (ALP) activity
ALP activity was quantitatively measured using a
commercial phosphatase assay kit (Sigma-Aldrich) ac-
cording to the manufacturer’s instructions. The cells
were lysed with celLytic M (Sigma-Aldrich) and
freeze-thawed at −20 °C and room temperature twice
to release the ALP. The lysate was transferred to 96-
well plates and incubated with ALP substrate at 37 °C
for 30 minutes. The reaction was stopped by addition
of the stop buffer. The p-nitrophenol product formed
by enzymatic hydrolysis of the p-nitrophenyl phos-
phate substrate was measured at 405 nm using a
microplate reader (SpectraMax M5, Bucher Biotec,
Basel, Switzerland).
Histological staining of cell mineralization
To visualize the amount of calcium deposition by
MSCs after 21 days of culture under osteogenic-
inducing conditions, the cells were fixed in 4 % for-
malin for 10 minutes and then stained with a 2 %
Alizarin red S solution (Sigma-Aldrich) for 45 mi-
nutes. The cells were washed with distilled water
three times and then once with phosphate-buffered
saline (PBS). High-resolution images were then
captured with a digital camera (Eclipse 800, Nikon,
Tokyo, Japan).
Immunocytochemical staining and detection of GREM1
and NOG in primary IVD cells
Passage-1 human NPCs and AFCs were grown on
glass coverslips for 48 h in 6-well plates at a density
of 5 × 104 cells/well in LG-DMEM containing 10 %
FBS, 100 U/ml penicillin, and 100 mg/ml strepto-
mycin. The cells were then fixed with 4 % buffered
paraformaldehyde for 10 minutes and stored in PBS
at 4 °C prior to staining. Cells were then perme-
abilized with 100 % methanol for 2 minutes, rehy-
drated in PBS for 2 minutes, blocked with 10 % FBS
in PBS for 1 h, and then incubated with primary anti-
bodies (1:200 dilutions) at 4 °C overnight. Antibodies were
rabbit anti-Gremlin-1 (sc-28873, Santa Cruz Biotechnol-
ogy Inc. Dallas, TX, US) and mouse anti-Noggin
(SAB3300029, Sigma-Aldrich) monoclonal antibodies for
double immunostaining. For the staining control, primary
antibodies were omitted. Secondary antibodies were added
at 1:1000 dilutions and incubated for 1 h at room
temperature (A-11008 Alexa Fluor 488 goat anti-rabbit
and Alexa Fluor 555 goat anti-mouse IGg2b (y2b),
Molecular Probes, Life Technologies, Basel, Switzerland).
The cells were visualized with a confocal laser scanning
microscope (cLSM710, Carl Zeiss, Jena, Germany) at × 63
magnification.
Fig. 1 Design of coculture experiments with human bone marrow-derived mesenchymal stem cells (MSCs) and intervertebral disc cells without cell contact.
Four experimental groups were cultured for 21 days. Controls were MSCs cultured in osteogenic medium (positive control) and MSCs cultured in growth
medium (negative control). The experimental groups were cocultures of MSCs with either nucleus pulposus cells (NPCs) or annulus fibrosus cells (AFCs)
Table 3 Primer sequences for real-time PCR analyses
Gene Forward primer Reverse primer
18S CGA TGC GGC GGC GTT ATT C TCT GTC AAT CCT GTC CGT GTC C
Alkaline phosphatase (ALP) GTA TGA GAG TGA CGA GAA AAT AGG TAG TCC ACA TTG T
Runt-related transcription factor 2 (RUNX2) AGC AGC ACT CCA TAT CTC T TTC CAT CAG CGT CAA CAC
Osteopontin (OPN) ACG CCG ACC AAG GAA AAC TC GTC CAT AAA CCA CAC TATC ACC TCG
Noggin (NOG) CAG CAC TAT CTC CAC ATC CG CAG CAG CGT CTC GTT CAG
Gremlin (GREM1) GAG AAG ACG ACG AGA GTA AGG AA CCA ACC AGT AGC AGA TGA ACA G
Chordin (CHRD) GTG GCT GCT GTG ACT CTG AAC AGG ACA CTG CCA TTG
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Statistics
Statistical analysis was performed using PRISM software
(version 6.0f, GraphPad, La Jolla, CA, USA). A value of p
<0.05 was considered to be significant. Ordinary one-
way analysis of variance with Tukey’s multiple compari-
son test was applied for all analyses.
Results
Histology of calcium deposition
MSCs grown in osteogenic medium had the greatest
calcium deposition (Fig. 2a), which served as the posi-
tive control. Coculture of MSCs and IVD cells re-
sulted in a reduction of mineralization as observed by
reduced alizarin red staining. These results were
comparable with MSCs cultured in growth medium
(negative control).
ALP activity in MSCs
After 21 days of culture, ALP activity was increased
in MSCs cultured in osteogenic medium compared
with the negative control (Fig. 2b). ALP activity of
the positive control was 318.7 ± 35.71 mU/ml, which
differed significantly from that of the negative control
(132.0 ± 31.84 mU/ml, p = 0.0045). MSC-NPC cocultures
did not differ from the negative control (p = 0.061).
However, MSC-AFC cocultures differed significantly from
the negative control (p = 0.003).
Relative gene expression of bone-related markers in
MSCs
Relative gene expression analysis of bone-related markers
showed higher ALP, Runx2, and OPN expression in the
positive control than that in the negative control (Fig. 2c).
Gene expression of ALP, Runx2, and OPN in cocultures
was comparable with the negative control. NOG gene ex-
pression was significantly increased in osteogenic cultures
compared with the negative control (p = 0.042, negative vs
positive controls; p = 0.001, negative control vs MSC-NPC
cocultures; p >0.0001, negative control vs MSC-AFC co-
cultures). Gene expression of NOG in MSCs was also
higher in MSC-AFC cocultures than in the positive con-
trol (p = 0.037).
Protein expression of NOG and GREM1 in IVD cells
To investigate the inhibitory effect of IVD cells on
osteogenic differentiation of MSCs, the intracellular pro-
tein expression of the major BMP antagonists, namely
NOG and GREM1, in IVD cells was detected by im-
munocytochemistry. NOG and GREM1 were both
expressed in IVD cells with more intense staining of
a
b c
Fig. 2 Osteogenic differentiation of bone marrow-derived mesenchymal stem cells (MSCs) in coculture with nucleus pulposus cells (NPCs) and annulus
fibrosus cells (AFCs). a Alizarin red staining. Macroscopic (top row) and microscopic images (bottom row, ×10 magnification) showed reduced alizarin
staining of MSCs in coculture with NPCs or AFCs compared with the positive control. Scale bar 100 μm. b Alkaline phosphatase (ALP) activity of MSCs
after 21 days (n = 5) showed an increase under all osteogenic conditions compared with the negative control. ALP activity was reduced in cocultures
of MSCs with NPCs and similar levels were found between cocultures of MSCs with AFCs and the positive control. c Relative gene expression of
osteogenic markers (ALP, RUNX2 and OPN) in MSCs in response to the presence of intervertebral disc (IVD) cells in alginate beads (n = 5). Cocultures
with IVD cells showed reduced gene expression of these osteogenic markers compared with the positive control. Furthermore, a significant increase in
gene expression of NOG was observed under the osteogenic condition: *p <0.05, **p <0.01, ***p <0.001, and #p <0.0001
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BMP antagonists in NPCs (Fig. 3a) compared with AFCs
(Fig. 3b). The expression of BMP antagonists was high-
est in a mixed IVD cell population (Fig. 3c).
Gene expression of DAN family members and Noggin in
IVD cells
To gain an insight into which BMP antagonists were re-
sponsible for the observed inhibition of osteogenic dif-
ferentiation, we measured the mRNA levels of major
BMP antagonists CHRD, NOG and GREM1 by real-time
RT-PCR. Gene expression levels were not significantly
different between NPCs and AFCs at low passages.
However, two-fold higher gene expression of GREM1
was observed in NPCs compared with AFCs (Fig. 3d).
Similarly, CHRD and NOG gene expression was 1.2-fold
higher in NPCs compared with AFCs.
Discussion
Implications for spinal non-fusion
Despite being the gold standard for treatment of disc-
related back pain, spinal fusion to form a vertebral bone
fusion over the disc space has a failure rate of up to
30 % [1, 2]. Although fusion may be improved by differ-
ent bone graft materials, a clinical study has demon-
strated that failure of spinal fusion may be due to the
presence of remaining disc tissue that might interfere
with the bone union process [3]. Li et al. [4] confirmed
this finding using a porcine spinal fusion model in which
the fusion rate was only 10 % when the autograft was
mixed with NP tissue compared with a fusion rate of up
to 70 % when the autograft only was used for fusion. For
optimal fusion, the mechanism of non-union must be
understood. We therefore investigated the effect of IVD
cells on osteogenesis of MSCs to gain an insight into
how to improve the ossification process of IVDs.
In this study, we investigated the influence of IVD cells
on MSC osteogenesis in a paracrine coculture model.
Relative gene expression, ALP activity, and histological
analyses showed that IVD cells inhibited osteogenesis of
MSCs. The exact mechanism of this inhibition is not
fully understood because full mechanistic insights are
lacking. We hypothesized that continuous expression of
BMP antagonists by IVD cells may interfere with the os-
sification process during spinal fusion. BMP signaling
Fig. 3 Expression of bone morphogenic protein antagonists Chordin, Gremlin, and Noggin in intervertebral disc (IVD) cells. a Immunocytochemistry of
GREM1 and NOG in monolayers of passage 1 nucleus pulposus cells (NPCs) (a), annulus fibrosus cells (AFCs) (b) and (c) mixed human IVD cells. GREM1
and NOG were both expressed in NPCs, whereas minimal expression of NOG, but not GREM1, was found in AFCs. GREM1 and NOG were highly
expressed in mixed cultures of NPCs and AFCs. d Quantification of BMP antagonist gene expression in NPCs relative to AFCs (n = 8 donors) at passage
1. NPC monolayer culture showed no differences in CHRD or NOG expression compared with NPCs and AFCs. GREM1 expression was 2-fold higher in
NPCs than in AFCs. DAPI 4',6-diamidino-2-phenylindole
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plays an essential role in skeletal tissue formation and
homeostasis, because it induces commitment of MSCs
toward osteoblasts [12]. In addition, BMP2 is applied in
orthopedics to accelerate bone healing in long bone
fractures and spinal fusion. BMP signals are tempered
by extracellular signals from BMP antagonists, such
as NOG, CHRD, GREM1, and twisted gastrulation
(TWSG1), which regulate BMP signal transduction
[16]. Physiological BMP antagonists negatively regu-
late BMP ligands [29], and timely regulation of BMPs
and BMP antagonists determines healing or non-
healing of bone fractures [30]. IVD cells secrete BMP
antagonists to regulate formation of the segmental
pattern during embryonic development [7, 10]. A
microarray study by Minogue et al. [31] indicated a
higher gene expression level of CHRD in the bovine
NP than the AF or chondrocytes.
To delineate the inhibitory effect of IVD cells on MSC
osteogenesis, we analyzed the endogenous expression of
major BMP antagonists (CHRD, NOG, and GREM1) in
IVD cells. We found that BMP antagonists were
expressed intracellularly by both human NPCs and
AFCs, and were abundant in NPCs. The differential ex-
pression of NOG and GREM1 in IVD cells can partly
explain the inhibitory effect on the osteogenic differenti-
ation of MSCs. However, it should be noted that,
because of insufficient human disc material, the isolated
cells were amplified in monolayer culture to compensate
for the low cell numbers, and the proteins were detected
by immunohistochemistry, which differs from the cocul-
ture conditions and their native matrix.
BMP antagonists
NOG is a major extracellular BMP antagonist that binds
to BMPs. It blocks BMP binding to BMP-specific recep-
tors, and therefore negatively regulates BMP-induced
osteogenesis [32, 33]. BMPs and NOG appear to be con-
tinuously secreted by IVD cells and the entire spine as a
potential regulatory mechanism to control bone forma-
tion, which is supported by our data and another study
in mice [34]. The balance between secretion of BMPs
and their antagonists is crucial to maintain normal mus-
culoskeletal functions. Several spinal diseases are caused
by dysregulation between bone and IVDs. Diffuse idio-
pathic skeletal hyperostosis [19, 35] and ankylosing
spondylitis (AS) [36] are of particular interest in the con-
text of BMP agonism and antagonism. Both diseases are
manifested by excessive bone formation in vertebrae and
entheses, although the two diseases presumably have a
different pathogenesis [19, 37]. Recently, Xie et al. [38]
found that MSCs from patients with AS express higher
levels of NOG and BMP2 compared with healthy sub-
jects. MSCs from patients with AS also exhibit a higher
osteogenic activity than MSCs from healthy donors [38].
Moreover, it has been demonstrated that NOG inhibits
migration of human umbilical vein endothelial cells. It
has been proposed that notochordal-rich tissue and no-
tochordal cell-conditioned medium [39] contain NOG
that might play a crucial role in preventing ingrowth of
blood vessels into the healthy disc by downregulation of
vascular endothelial growth factor signaling. This obser-
vation is in line with our finding of strong positive stain-
ing for NOG in NPCs but not in AFCs.
Another BMP antagonist, GREM1, has been recently
shown to play a crucial role in a dormant stem cell
population that is able to differentiate into cartilage and
bone, and even has a reticular stromal potential [40].
GREM1 binds preferentially to BMP2 over BMP4 or
BMP7 [41]. Therefore, GREM1 represents a potential
therapeutic target to improve spinal fusion therapy,
because of the high doses of BMP2 used during spinal
fusion surgery. CHRD has been reported to be expressed
in both bovine and human IVD tissues [17]. The binding
of CHRD to BMPs also plays an important role in shap-
ing the BMP morphogenetic field during vertebral devel-
opment in mouse embryos [8].
Traditionally, the ideal material for fusion has been an
iliac crest bone graft. Because of the high rate of postop-
erative pain and morbidity, bone graft replacement ma-
terials with osteoconductive and osteogenic properties,
such as demineralized bone matrix, recombinant growth
factors, and synthetic implants, have been under exten-
sive investigation. BMP2 has been introduced as one of
the most popular alternatives to autologous bone grafts
to enhance spinal fusion, but its effectiveness is still the
subject of debate [20]. It has been suggested that the
osteoconductive activity of the high dose of injected
BMPs might be mitigated by cytokines of the DAN fam-
ily [18] and BMP antagonists such as NOG [16, 21]. A
study has shown that an increased BMP concentration
induces the expression of BMP antagonists to regulate
the amount of osteogenic activity. Therefore, the
injected BMP may have a limited ability to induce osteo-
blast activity because of the intrinsic regulation of BMP
activity [42]. Because of the tendency for IVD cells to
maintain a balance between BMPs and their antagonists,
the action of exogenous BMP2 might be tempered by
BMP antagonists secreted from endogenous IVD cells
during spinal fusion. Our findings suggest that future
therapeutics targeting BMP antagonist signaling path-
ways might enhance the osteogenic differentiation of
MSCs, and therefore the outcome of spinal fusion sur-
gery. Through understanding of regulatory systems and
BMP signaling pathways, potential drugs targets may be
identified to regulate BMP signals in the process of bone
formation [21, 43].
When identifying potential factors to enhance osteo-
genesis, the binding affinity of BMP antagonists should
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be considered, because they have different affinities for
different BMPs. For example, GREM1 preferentially
binds to BMP2, BMP4, and BMP7 [41]. BMP9 may be a
more potent osteogenic growth factor than BMP2 be-
cause of its resistance to BMP antagonists [44, 45].
BMP9 gene therapy has been shown to improve bone
formation during fusion in a rodent model [46]. Intracel-
lular BMP signaling is regulated by the action of inhibi-
tory Smads 6 and 7 that stably bind to type I BMP
receptors, thus interfering with Smad-1/5/8 phosphoryl-
ation and heterodimerization with Smad4 [43]. On the
other hand, the transducer of the ErbB2 gene decreases
BMP signaling by binding to type I BMP receptors at
the plasma membrane and sequestering Smad-1/5/8. In-
activation of the ErbB2 gene in mice leads to increases
in bone formation and the number of osteoblasts [47].
Moreover, blocking BMP antagonists might be an option
to enhance osteogenesis [48]. Downregulation of NOG
by NOG-short-hairpin-RNA (shRNA) or small interfer-
ing RNA (siRNA) enhances osteogenesis of adipose-
derived MSCs [49] and enhances BMP activity in C2C12
cells [50]. CHRD knockdown by siRNA also enhances
osteogenesis of human MSCs [51]. An in-silico study has
designed drugs that might interfere with BMP2/NOG
binding, but the functions of these drugs still need to be
tested [52]. Thus, future experiments should focus on
experimental over-expression and/or silencing of specific
BMPs and titration of antagonists using clinically rele-
vant primary cells [38].
Our study demonstrated that osteogenesis of bone
marrow-derived MSCs is inhibited by IVD cells, and that
BMP antagonists are expressed by adult human IVD
cells. GREM1 and NOG were more expressed in NPCs
than AFCs. At the mRNA level, we found about two-
fold higher expression of GREM1 in NPCs than in AFCs.
Our study is limited because we did not check for its ex-
pression in the MSC coculture experiment. In addition,
other potent BMP antagonists that have been described
to play a role in bone homeostasis, such as TWSG-1 and
follistatin, should be investigated in more detail in future
experiments. In this respect, the role of the chondro-
cytes in the cartilaginous endplate (CE) should be inves-
tigated more deeply in future studies, because the CE
cells more frequently remain in the gap during discec-
tomy than NPCs or AFCs.
Conclusions
In summary, our study provides evidence of inhibition
of osteogenic differentiation in MSCs by coculture with
IVD cells. The underlying mechanism is unknown, but
this effect can be explained partly by the expression of
BMP antagonists, namely NOG and GREM1, by IVD
cells when cocultured with MSCs. Targeting these BMP
antagonists might be a therapeutic strategy to improve
and accelerate the spinal fusion process. In future stud-
ies, we will test approaches to inhibit the release of BMP
antagonists in vitro and in vivo to induce osteogenic dif-
ferentiation and improve the outcome of spinal fusion.
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